Name in SEC filings: Zenas BioPharma, Inc.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| ZB021 | /data readout | Stage not stated | year-end 2026 | 8-K · |
| obexelimab | Topline/data readout | Phase 2 | fourth quarter of 2026 | 8-K · |
| obexelimab | target date (company stated) | PDUFA | May 27, 2027 | 8-K · |
| ZB021 | Topline/data readout | Stage not stated | 2027 | 8-K · |
Source: ORION, orionbiotechai.com/company/ZBIO, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/ZBIO
ZB021 · Topline/data readout · year-end 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutyear-end 2026
Stage: Not stated
Public float: $259,300,000 · as of · SEC filing
These data are expected by year-end 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutfourth quarter of 2026
Stage: Phase 2SEC filing · “Phase 2; Phase 2”
Public float: $259,300,000 · as of · SEC filing
Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026: Zenas anticipates reporting topline overall and biomarker population results in the fourth quarter of 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
PDUFA target date (company stated)May 27, 2027
Stage: PDUFASEC filing · “PDUFA) target action date”
Public float: $259,300,000 · as of · SEC filing
The BLA has a Prescription Drug User Fee Act (PDUFA) target action date of May 27, 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-05)
Topline/data readout2027
Stage: Not stated
Public float: $259,300,000 · as of · SEC filing
Upon completion and evaluation of the SAD and MAD study, Zenas plans to initiate a proof-of-concept (POC) trial in North America to evaluate clinical activity and safety in psoriasis patients with results anticipated in 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| obexelimabFDA decision | May 27, 2027“The BLA has a Prescription Drug User Fee Act (PDUFA) target action date of May 27, 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| obexelimabClinical results | fourth quarter of 2026“Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026: Zenas anticipates reporting topline overall and biomarker population results in the fourth quarter of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| ZB021Clinical results | 2027“Upon completion and evaluation of the SAD and MAD study, Zenas plans to initiate a proof-of-concept (POC) trial in North America to evaluate clinical activity and safety in psoriasis patients with results anticipated in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| ZB021Clinical results | year-end 2026“These data are expected by year-end 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| obexelimabClinical results | fourth quarter 2026“we expect to report topline results, including biomarker data, in the fourth quarter 2026.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| obexelimabClinical results | fourth quarter of 2026“In April 2026, we completed enrollment in the SunStone trial and expect to report topline results, including biomarker data, in the fourth quarter of 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| obexelimabClinical results | 2026“Enrollment completed in Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) and topline results expected in 4Q 2026” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| obexelimabClinical results | fourth quarter of 2026“Zenas anticipates reporting topline overall and biomarker population results in the fourth quarter of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| ZB021Clinical results | 2027“Upon completion and evaluation of the SAD and MAD study, Zenas plans to initiate a proof-of-concept (POC) trial in North America to evaluate clinical activity and safety in psoriasis patients with results anticipated in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| ZB021Clinical results | year-end 2026“These data are expected by year-end 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| obexelimabClinical results | fourth quarter of 2026“we expect to report topline results, including biomarker data, in the fourth quarter of 2026.” Filed · 10-K | Still within period As of Oct 19, 2026 |
| obexelimabClinical results | fourth quarter of 2026“We expect to report data on the primary endpoint at 24 weeks and biomarker data in the fourth quarter of 2026.” Filed · 10-K | Still within period As of Oct 19, 2026 |
| obexelimabClinical results | fourth quarter 2026“we expect to report topline results, including biomarker data, in the fourth quarter 2026.” Filed · 10-K | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| obexelimabClinical results | fourth quarter of 2026“We expect to report topline results, including biomarker data, from the SunStone trial, including biomarker data, in the fourth quarter of 2026.” Filed · 10-K | Still within period As of Oct 19, 2026 |
| obexelimabClinical results | mid-2026“We expect to complete enrollment in the SunStone trial by year-end 2025 and to report topline results from the SunStone trial in mid-2026.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for ZBIO. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See ZBIO in the calendar · Review labels and methodology